

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

➤ *Limited Use & License Disclosure*

BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed.
"Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

Human BDCA2 (Luc) Jurkat Reporter Cell


Catalog No.	Size
CJUR-STF322	2 × (1 vial contains $\sim 5 \times 10^6$ cells)

• Description

The Human BDCA2 (Luc) Jurkat Reporter Cell was engineered to not only express NFAT signaling response element, but also express the receptor full length human BDCA2 (Uniprot: Q8WTT0-1). When cocultured with anti-human BDCA2 agonist antibody, the interaction of agonist antibody and BDCA2 on the surface of Human BDCA2 (Luc) Jurkat Reporter Cell results in NFAT-mediated luminescence.

• Application

- Screen for anti-human BDCA2 agonist antibody.



Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• Cell Line Profile

Cell line	Human BDCA2 (Luc) Jurkat Reporter Cell
Host Cell	Jurkat
Property	Suspension
Complete Growth Medium	RPMI-1640 + 10% FBS
Selection Marker	Puromycin (5 µg/mL) + Hygromycin B (20 µg/mL)
Incubation	37°C with 5% CO ₂
Doubling Time	16-20 hours
Transduction Technique	Lentivirus

• Materials Required for Cell Culture

- RPMI Medium 1640 (Gibco, Cat. No. 11875-093)
- Fetal bovine serum (CellMax, Cat. No. SA211.02)
- Puromycin (InvivoGen, Cat. No. ant-pr-5b)
- Hygromycin B (Invitrogen, Cat. No. 10687010)

Note: For selection antibiotics, we highly recommend using the specified brand. The activity of antibiotics may vary between manufacturers, so if you choose to use a different brand, it is essential to validate whether the concentration recommended in the culture medium is suitable. Regardless of the brand used, we recommend maintaining a backup culture without selection antibiotics to avoid potential cell loss due to inappropriate antibiotic concentration.

- Penicillin-Streptomycin (Gibco, Cat. No. 15140-122)
- Complete Growth Medium: RPMI-1640 + 10% FBS, 1%P/S
- Culture Medium: RPMI-1640 + 10% FBS, Puromycin (5 µg/mL), Hygromycin B (20 µg/mL), 1%P/S
- Freeze Medium: 90% FBS, 10% (V/V) DMSO
- T-75 Culture flask (Corning, Cat. No. 430641)
- Cryogenic storage vials (SARSTEDT, Cat. No. 72.379.007)
- Thermostat water bath
- Centrifuge (Cence, Model: L550)
- Cell counter (MONWEI, Model: SmartCell200A Plus)
- CO₂ Incubator (Thermo, Model: 3111)
- Biological Safety Cabinet (Thermo, Model: 1389)

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• *Recovery*

1. Thaw the vial by gently agitating it in a 37°C water bath. To minimize the risk of contamination, ensure the cap remains out of the water. Thawing should be completed quickly, typically within 3-5 minutes.
2. After thawing, promptly remove the vial from the water bath and decontaminate it by spraying with 70% ethanol. From this point onward, all operations must be performed under strict aseptic conditions.
3. Transfer the contents of the vial to a centrifuge tube containing 4.0 mL of complete growth medium.
4. Count viable cells and centrifuge at approximately 1000 rpm for 5 minutes.
5. Discard the supernatant and resuspend the cell pellet in an appropriate amount of fresh **complete growth medium**. Adjust the cell density of the suspension to 1×10^6 viable cells/mL and transfer cells to an appropriate size vessel.
6. Incubate at 37°C with 5% CO₂ incubator.

• *Subculture*

Cell viability may be low after thawing, and full recovery (viability >90%) may take up to 1-2 weeks. Once the cell density reaches approximately 2×10^6 viable cells/mL, adjust the density to a range of 2×10^5 - 5×10^5 viable cells/mL by either adding the fresh **culture medium** or replacing the existing culture medium. Avoid allowing the cell density to exceed 3×10^6 cells/mL, as this may negatively impact cell performance in subsequent passages. T-75 flasks are recommended for subculturing.

• **Subculturing Frequency:** It is recommended to subculture every 3-4 days, adjusting the frequency based on the cell density in your specific culture system.

Note: After recovery, maintain the cells for 1-2 passages in the **complete growth medium** not containing the selection marker, if the cells are in good condition (viability >90%), transition to the **culture medium** containing the selection marker during subculturing.

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• *Cryopreservation*

1. Count viable cells and harvest the cell suspension.
2. Centrifuge at 1000 rpm for 5 min at room temperature and resuspend cells in ice cold freezing medium to a concentration of 5×10^6 to 1×10^7 cells/mL.
3. Aliquot the cell suspension into cryogenic storage vials. Place the vials in a programmable cooler or an insulated box placed in a -80°C freezer overnight, then transfer to liquid nitrogen storage for long-term storage.

Note: It is recommended to establish a cell bank at the earliest possible passage for long-term use.

• *Storage*

Cells must be received in a frozen state on dry ice and should be transferred to liquid nitrogen or a -80°C freezer immediately upon receipt. If stored in a -80°C freezer, it is recommended to limit the storage period to no more than two weeks. For long-term preservation, transfer the cells to liquid nitrogen is highly recommended.

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• Receptor Assay




Fig1. Expression analysis of human BDCA2 on Human BDCA2 (Luc) Jurkat Reporter Cell by FACS. Cell surface staining was performed on Human BDCA2 (Luc) Jurkat Reporter Cell or negative control cell using PE-labeled anti-human BDCA2 antibody.

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• Application

Anti-human BDCA2 Agonist Antibody Screening (RLU)




Fig2. Agonistic activity analysis of anti-human BDCA2 antibody (RLU). This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO cells or CHO/Human CD32b Stable Cell Line (Medium Expression) (Cat. No. SCCHO-ATP060M). The EC50 of Litifilimab determined in the presence of CHO cells was approximately 0.4915 $\mu\text{g/mL}$, and in the presence of CHO/Human CD32b Stable Cell Line (Medium Expression) was approximately 0.1866 $\mu\text{g/mL}$. These results demonstrate that Litifilimab can activate BDCA2 signaling independent of CD32b-mediated crosslinking, but the presence of CD32b can enhance BDCA2 signaling.

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

Anti-human BDCA2 Agonist Antibody Screening (FOLD)




Fig3. Agonistic activity analysis of anti-human BDCA2 antibody (FOLD). This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO cells or CHO/Human CD32b Stable Cell Line (Medium Expression) (Cat. No. SCCHO-ATP060M). The max induction fold of Litifilimab determined in the presence of CHO cells was approximately 81.03, and in the presence of CHO/Human CD32b Stable Cell Line (Medium Expression) was approximately 190.72. These results demonstrate that Litifilimab can activate BDCA2 signaling independent of CD32b-mediated crosslinking, but the presence of CD32b can enhance BDCA2 signaling.

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• *Related Products*

<u>Products</u>	<u>Cat.No.</u>
Human TSLP R (Luc) HEK293 Reporter Cell	CHEK-ATF045
STAT3 (Luc) HEK293 Reporter Cell	CHEK-ATF047
HEK293/Human CD40 Ligand / TNFSF5 Stable Cell Line	CHEK-ATP041
HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line	CHEK-ATP053
HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line	CHEK-ATP054
Human IL-5 R alpha/CD131 (Luc) HEK293 Reporter Cell	CHEK-ATF074
HEK293/FcRn (FCGRT & B2M) Cell Line	CHEK-ATP079
Human IL-21 R (Luc) HEK293 Reporter Cell	CHEK-ATF051
Human IL-11 R alpha (Luc) HEK293 Reporter Cell	CHEK-ATF052
Human IL-4 R alpha/IL-13 R alpha 1 (Luc) HEK293 Reporter Cell	CHEK-ATF075
CHO/Human TSHR Stable Cell Line	SCCHO-ATP085
HEK293/Human TSHR Stable Cell Line	CHEK-ATP086
Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell	CHEK-ATF094
Human IL-10 R alpha/IL-10 R beta (Luc) HEK293 Reporter Cell	CHEK-ATF095
Human CD40 (Luc) HEK293 Reporter Cell	CHEK-ATF097
Human IL-7 R alpha/CD132 (Luc) HEK293 Reporter Cell	CHEK-ATF099
NIH-3T3/Human IGF-1 R Stable Cell Line Development Service	CNIH-ATP102
Human HVEM (Luc) HEK293 Reporter Cell	CHEK-ATF105
Human BTLA (Luc) Jurkat Reporter Cell	SCJUR-STF106
Human IGF-1 R (Luc) HEK293 Reporter Cell	CHEK-ATF107
Human GLP-2R (Luc) HEK293 Reporter Cell	CHEK-ATF128
Human RANK (Luc) HEK293 Reporter Cell	CHEK-ATF129
HEK293/FcRn (FCGRT & B2M), GFP Tag Stable Cell Line	CHEK-ATP132
Human IL-17 RA/IL-17 RC (Luc) HEK293 Reporter Cell	CHEK-ATF133
Human OX40 (Luc) HEK293 Reporter Cell	CHEK-ATF135

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• *Related Products*

<u>Products</u>	<u>Cat.No.</u>
Human IL-2 R beta/IL-2 R gamma (Luc) HEK293 Reporter Cell	CHEK-ATF136
HEK293/Human TL1A Stable Cell Line	CHEK-ATP142
Human IL-23 R/IL-12 R beta 1(Luc) HEK293 Reporter Cell	CHEK-ATF166
Human IL-22 R alpha 1/IL-10 R beta (Luc) HEK293 Reporter Cell	CHEK-ATF167
Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell	SCJUR-STF178
Human TSHR (Luc) HEK293 Reporter Cell	CHEK-ATF187
CHO/Mouse FCGRT-P2A-mGFP&B2M Stable Cell Line	SCCHO-ATP193
Human PTH1R (Luc) HEK293 Reporter Cell	CHEK-ATF194
MDCK/Mouse FCGRT-P2A-mGFP&B2M Stable Cell Line Development Service	SCMDC-ATP196
Human TACI (Luc) HEK293 Reporter Cell	CHEK-ATF197
HEK293/Membrane-Bound Human TL1A Stable Cell Line	CHEK-ATP198
Human IL-2 R alpha & IL-2 R beta & IL-2 R gamma (Luc) HEK293 Reporter Cell	CHEK-ATF201
Human IL-1 R1 & IL-1 RAcP (Luc) HEK293 Reporter Cell	CHEK-ATF202
Raji/Membrane-Bound Human TL1A Stable Cell Line	SCRAJ-STT204
HEK293/Human MRGPRX2 Stable Cell Line	CHEK-ATP214
CHO/Human MRGPRX2 Stable Cell Line	SCCHO-ATP215
Human TPO R (Luc) HEK293 Reporter Cell	CHEK-ATF226
CHO/Human CD89 Stable Cell Line	SCCHO-ATP225
Raji/Human TL1A Stable Cell Line	CRAJ-STP232
Human IL-18 R1/IL-18 R beta (Luc) HEK293 Reporter Cell	CHEK-ATF233
Human IL-17 RA/IL-17 RB (Luc) HEK293 Reporter Cell	CHEK-ATF239
CHO/Human MAdCAM-1 Stable Cell Line	CCHO-ATP241
HEK293/Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Stable Cell Line	CHEK-ATP243

Human BDCA2 (Luc) Jurkat Reporter Cell Data Sheet

• *Related Products*

<u>Products</u>	<u>Cat.No.</u>
Human IL-1RL1 & IL-1 RAcP (IL-33 receptor) (Luc) HEK293 Reporter Cell	CHEK-ATF244
Jurkat/Human Transmembrane TNF-alpha (mTNF) Stable Cell Line	CJUR-STF248
CHO/Human CXCR3 Stable Cell Line	CCHO-ATP252
HEK293/Human CXCR3 Stable Cell Line	CHEK-ATP253
Human Glucocorticoid Receptor (Luc) HEK293 Reporter Cell	CHEK-ATF264
Human PD-1 & IL-2 R alpha & IL-2 R beta & IL-2 R gamma (Luc) HEK293 Reporter Cell	CHEK-ATF265
Human BCMA (Luc) HEK293 Reporter Cell	CHEK-ATF296